BioChem, XTL deal

BCHXF's BioChem Therapeutic Inc. subsidiary and XTL will collaborate to discover drugs to treat hepatitis C infections. The alliance will combine BioChem's expertise in medicinal chemistry and virology with XTL's Trimera technology, which can be used to model hepatitis B and C infections in vivo.

The agreement follows XTL's achievement of certain technical goals with Trimera defined in a 1995 option agreement between the companies. ...